Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

The incidence of melanoma is increasing worldwide, and the prognosis for patients with
high‐risk or advanced metastatic melanoma remains poor despite advances in the field …

Marching into the second decade after the approval of ipilimumab, it is clear that immune
checkpoint inhibitors (ICIs) have dramatically improved the prognosis of melanoma …

Summation Cancer immunotherapy consists of approaches that modify the host immune
system, and/or the utilization of components of the immune system, as cancer treatment …

Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at
the price of a new array of immune related adverse events. Among these is β-cell failure …

Cancer is the second leading cause of death globally and its incidence and mortality are
rapidly increasing worldwide. The dynamic interaction of immune cells and tumor cells …

Purpose Elesclomol is a novel, small-molecule, oxidative stress inducer believed to exert
selective cytotoxicity by increasing intracellular concentrations of reactive oxygen species …

The number of melanoma cases worldwide is increasing faster than any other cancer and
remains one of the most treatment-refractory malignancies. Despite decades of clinical trials …

Background: Current immunomodulatory agents for stage III and IV melanoma exert different
mechanisms of action that manifest in distinct adverse events. Objective: This systematic …

Chemotherapy, biological agents or combinations of both have had little impact on survival
of patients with metastatic melanoma. Advances in understanding the genetic changes …